The inhibitory quotient. A method for interpreting minimum inhibitory concentration data

P. D. Ellner and H. C. Neu

A method for reporting minimum inhibitory concentration (MIC) data that facilitates interpretation by the clinician unfamiliar with clinically achievable drug levels is described. This system uses the inhibitory quotient, which is a number reflecting the multiple of the MIC that would be achieved. Inhibitory quotients are determined for blood, urine, bile, and CSF and reflect achievable drug levels in those body fluids. The use of inhibitory quotients can be extremely helpful to the physician in the rational selection of an appropriate antimicrobial agent.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pharmacokinetics of High-Dose Lopinavir-Ritonavir with and without Saquinavir or Nonnucleoside Reverse Transcriptase Inhibitors in Human Immunodeficiency Virus-Infected Pediatric and Adolescent Patients Previously Treated with Protease Inhibitors
Robbins et al.
Antimicrob. Agents Chemother. 2008;52:3276-3283.
ABSTRACT | FULL TEXT  

Setting and Revising Antibacterial Susceptibility Breakpoints
Turnidge and Paterson
Clin. Microbiol. Rev. 2007;20:391-408.
ABSTRACT | FULL TEXT  

Activity of Gatifloxacin in an In Vitro Pharmacokinetic-Pharmacodynamic Model against Staphylococcus aureus Strains either Susceptible to Ciprofloxacin or Exhibiting Various Levels and Mechanisms of Ciprofloxacin Resistance.
Ba et al.
Antimicrob. Agents Chemother. 2006;50:1931-1936.
ABSTRACT | FULL TEXT  

Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection
Moskowitz et al.
J Antimicrob Chemother 2005;56:879-886.
ABSTRACT | FULL TEXT  

Estimation of Serum-Free 50-Percent Inhibitory Concentrations for Human Immunodeficiency Virus Protease Inhibitors Lopinavir and Ritonavir
Hickman et al.
Antimicrob. Agents Chemother. 2004;48:2911-2917.
ABSTRACT | FULL TEXT  

Activities of Ciprofloxacin and Moxifloxacin against Stenotrophomonas maltophilia and Emergence of Resistant Mutants in an In Vitro Pharmacokinetic-Pharmacodynamic Model
Ba et al.
Antimicrob. Agents Chemother. 2004;48:946-953.
ABSTRACT | FULL TEXT  

Pharmacological indices in antibiotic therapy
Barger et al.
J Antimicrob Chemother 2003;52:893-898.
ABSTRACT | FULL TEXT  

Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients
Hsu et al.
Antimicrob. Agents Chemother. 2003;47:350-359.
ABSTRACT | FULL TEXT  

Virtual Inhibitory Quotient Predicts Response to Ritonavir Boosting of Indinavir-Based Therapy in Human Immunodeficiency Virus-Infected Patients with Ongoing Viremia
Shulman et al.
Antimicrob. Agents Chemother. 2002;46:3907-3916.
ABSTRACT | FULL TEXT  

The Significance of Serum vs Tissue Levels of Antibiotics in the Treatment of Penicillin-Resistant Streptococcus pneumoniae and Community-Acquired Pneumonia: Are We Looking in the Wrong Place?
Siegel
Chest 1999;116:535-538.
FULL TEXT  

Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics
Groll et al.
J Antimicrob Chemother 1999;43:95-103.
ABSTRACT | FULL TEXT  

Comparisons between Antimicrobial Pharmacodynamic Indices and Bacterial Killing as Described by Using the Zhi Model
Corvaisier et al.
Antimicrob. Agents Chemother. 1998;42:1731-1737.
ABSTRACT | FULL TEXT